BIOMEA FUSION INC (BMEA) Stock Price, Quote, News and Overview
NASDAQ:BMEA - Nasdaq - US09077A1060 - Common Stock - Currency: USD
BMEA Quote, Performance and Key Statistics
2.71
-0.09 (-3.21%)
The current stock price of BMEA is 2.71 USD. In the past month the price decreased by -34.22%. In the past year, price decreased by -82.36%.
BMEA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About BMEA
Company Profile
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. The company is headquartered in Redwood City, California and currently employs 107 full-time employees. The company went IPO on 2021-04-16. The firm is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The firm is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. The company is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Company Info
BIOMEA FUSION INC
900 Middlefield Road, 4th Floor
Redwood City CALIFORNIA US
Employees: 112
Company Website: https://www.biomeafusion.com/
Investor Relations: http://investors.biomeafusion.com
Phone: 16509809099
BIOMEA FUSION INC / BMEA FAQ
What is the stock price of BIOMEA FUSION INC today?
The current stock price of BMEA is 2.71 USD. The price decreased by -3.21% in the last trading session.
What is the ticker symbol for BIOMEA FUSION INC stock?
The exchange symbol of BIOMEA FUSION INC is BMEA and it is listed on the Nasdaq exchange.
On which exchange is BMEA stock listed?
BMEA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOMEA FUSION INC stock?
15 analysts have analysed BMEA and the average price target is 30.86 USD. This implies a price increase of 1038.56% is expected in the next year compared to the current price of 2.71. Check the BIOMEA FUSION INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOMEA FUSION INC worth?
BIOMEA FUSION INC (BMEA) has a market capitalization of 98.21M USD. This makes BMEA a Micro Cap stock.
How many employees does BIOMEA FUSION INC have?
BIOMEA FUSION INC (BMEA) currently has 112 employees.
What are the support and resistance levels for BIOMEA FUSION INC (BMEA) stock?
BIOMEA FUSION INC (BMEA) has a resistance level at 2.92. Check the full technical report for a detailed analysis of BMEA support and resistance levels.
Should I buy BIOMEA FUSION INC (BMEA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BMEA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BMEA, evaluating the profitability, health, valuation and growth aspects
- BIOMEA FUSION INC (BMEA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOMEA FUSION INC (BMEA) Sales and EPS estimates to see what analysts future expectations are.
- BIOMEA FUSION INC (BMEA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOMEA FUSION INC (BMEA) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOMEA FUSION INC (BMEA) Stock Chart to make your own analysis
- BIOMEA FUSION INC (BMEA) Latest news and press-releases to stay up to date.
Does BIOMEA FUSION INC (BMEA) stock pay dividends?
BMEA does not pay a dividend.
What is the Price/Earnings (PE) ratio of BIOMEA FUSION INC (BMEA)?
BIOMEA FUSION INC (BMEA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.01).
What is the Short Interest ratio of BIOMEA FUSION INC (BMEA) stock?
The outstanding short interest for BIOMEA FUSION INC (BMEA) is 40.56% of its float. Check the ownership tab for more information on the BMEA short interest.
BMEA Technical Analysis
BMEA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BMEA. The financial health of BMEA is average, but there are quite some concerns on its profitability.
BMEA Financial Highlights
Over the last trailing twelve months BMEA reported a non-GAAP Earnings per Share(EPS) of -4.01. The EPS decreased by -20.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -130.42% | ||
| ROE | -189.55% | ||
| Debt/Equity | 0 |
BMEA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 81% to BMEA. The Buy consensus is the average rating of analysts ratings from 15 analysts.